期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

食管癌组织中HER-2/neu蛋白表达和基因扩增的检测及其临床意义 被引量：3

Clinicopathological implication of HER-2/neu protein expression and gene amplication in esophageal carcinoma
下载PDF
导出
摘要 目的:检测食管癌组织中HER-2/neu蛋白表达及其基因扩增情况,并探讨其与食管癌患者临床病理指标的关系。方法:回顾性分析2000～2006年武汉大学人民医院收治的167例食管癌患者的临床资料。采用免疫组织化学和荧光原位杂交方法检测167例食管癌患者癌组织中HER-2/neu蛋白表达及基因扩增情况。结果:食管癌组织中HER-2/neu蛋白表达水平与基因扩增存在一定相关性(P<0.05),HER-2/neu蛋白的表达与食管癌分化程度和临床分期有关系(P<0.05),而HER-2/neu基因扩增仅与食管癌临床分期有关系(p<0.05)。HER-2/neu蛋白过表达和基因扩增阳性均可缩短食管癌患者的生存期(P<0.05)。结论:HER-2/neu蛋白过表达及基因扩增可能是食管癌患者的一个预后指标,联合检测HER-2/neu蛋白表达水平及基因扩增程度对于食管癌的靶向治疗可能具有一定指导意义。 OBJECTIVE： To investigate HER-2/neu protein expression and gene amplication in esophageal carcinoma and to explore their clinicopathological in Renmin Hospital of Wuhan University, from gene status in 167 esophageal carcinomas were hybridization （FISH）. Categorical variables were correlations. METHODS： The clinical data of 167 patients admitted 2000 to 2006, were reviewed.The HER-2/neu protein expression and evaluated using immunohistochemistry （IHC） and fluorescence in situ compared by the Pearson chi-square test or Fisher＇s exact test and the survival rate was calculated by the Kaplan-Meier method and the log-rank test. RESULTS： HER-2 overexpression associated significantly with HER-2 gene amplification.There was a correlation between the overexpression of HER-2 and the differentiation of the carcinoma, the HER-2 gene amplification and the differentiation and stage of the carcinoma. According to univariate analysis, there was a significant difference in survival rates when cases with and without HER- 2/neu overexpression or amplification were compared. CONCLUSION： HER-2/neu amplification may constitute an independent prognostic factor in esophageal squamous cancer patients, and patients exhibiting HER-2/neu amplification might constitute potential candidates for new adjuvant therapies which involve the use of humanized monoclonal antibodies.
作者 汤永飞 詹娜 黄亚冰 刘琳
机构地区 武汉大学人民医院病理科
出处 《癌变．畸变．突变》 CAS CSCD 2012年第4期256-260,共5页 Carcinogenesis,Teratogenesis & Mutagenesis
关键词 食管癌 HER-2/NEU 免疫组织化学 荧光原位杂交 esophageal carcinoma HER-2/neu immunohistochemistry fluorescence in situ hybridization
分类号 R735.1 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer[J]. Am J Clin Pathol, 1999, 112 (Sup 1): 53-.67.
  • 2Yarden Y, Sliwkowski X. Untangling the ErbB signaling network[J]. Nat Rev Mol Cell Biol, 2001, 2 (2): 127-137.
  • 3Menard S, Casalini P, Campiglio M, et al. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer[J]. Ann Oncol, 2001, 12 (Sup): 15-19.
  • 4Mimura K, Kono K, Hanawa M, et al. Frequencies of HER-2/ neu expression and gene amplification in patients with oesophageal squamous cell carcinoma[J]. Br J Cancer, 2005, 92 (7): 1253-1260.
  • 5Sato-Kuwabara Y, Neves JI, Fregnani JH, et al. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization(FISH) and immunohistochemistry[J]. BMC Cancer, 2009, 9 (6): 1207-1471.
  • 6Hardwick RH, Barham CP, Ozua P, et al. Immunohistochemical detection of p53 and c - erbB - 2 in oesophageal carcinoma, no correlation with prognosis[J]. Eur J Surg Oncol, 1997, 23 (1): 30-35.
  • 7Lain KY, Tin L, Ma L. C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions[J]. Eur J Surg Oncol, 1998, 24(5): 431-435.
  • 8Dreilich M, Wanders A, Brattstrm D, et al. HER-2overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival[J]. Dis Esophagus, 2006, 19 (4): 224-231.
  • 9Tubbs RR, Pettay JD, Roche PC. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message[J]. J Clin Oncol, 2001, 19 (10): 2714-2721.
  • 10Bae CD, Juhnn YS, Park JB, et al. Post-transcriptional control of c-erbB-2 overexpression in stomach cancer cells[J]. Exp Mol Med, 2001, 33(1): 15-19.

二级参考文献22

  • 1葛棣,冯明祥,曾亮.表皮生长因子受体家族在食管癌中表达的临床研究[J].中国临床医学,2004,11(5):717-720. 被引量：11
  • 2王巍,辛晓燕,刘玉,郭会玲.宫颈癌组织中HER-2/neu和Ras表达的意义[J].第四军医大学学报,2006,27(19):1805-1807. 被引量：6
  • 3Agus DB, Bunn PA Jr, Franklin W, et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer [J]. Semin Oncol, 2000, 27(6 Suppl 11 ) :53 -63.
  • 4Park JW, Neve RM, Szollosi J, et al. Unraveling the biologic and clinical complexities of HER2 [ J ]. Clin Breast Cancer, 2008, 8(5) :592-401.
  • 5Reichelt U, Duesedau P, Tsourlakis MC, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus [ J]. Mod Pathol, 2007, 20 ( 1 ) : 120 - 129.
  • 6Mimura K, Kono K, Hanawa M,et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma [ J ]. Br J Cancer, 2005,92 (7) :1253 -1260.
  • 7Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated anti- body-dependent ceUular cytotoxicity against esophageal squamous cell carcinoma [ J]. Clin Cancer Res, 2005, 11 ( 13 ) :4898 -4904.
  • 8Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors [J]. Cancer Treat Rev, 2009, 35(2):121 -136.
  • 9Dowsett M, Procter M, Mecaskill-Stevens W. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of Trastuzumab: The HERA trial [J]. J Clin Oncol, 2009, 4(13) :132 -141.
  • 10Perez EA. Carboplatin in combination therapy for metastatic breast cancer [ J ]. Oncolagist, 2004, 9 (5):518- 527.

共引文献17

同被引文献63

  • 1Yoneda T, Kumagai T, Nagatomo I, et al. The extracellular domain of p185c-neu induces density-dependent inhibition of cell growth in malignant mesothelioma cell and reduces growth of mesothelioma in vivo [ J]. DNA Cell Biol,2006,25 (9) :530-540.
  • 2Purwanto I, Kumianda J, Hariadi KW, et al. Concentration of serum HER-2/nue as a prognostic factor in locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [J]. Acta Med In- dones,2011,43 ( 1 ) :23.
  • 3Mimura K, Kono K, Hanawa M, et al. Frequencies of HER-2/neu ex- pression and gene amplification in patients with oesophageal squamous cell carcinoma [ J ]. Br J Cancer, 2005,92 ( 7 ) : 1253-1260.
  • 4Sato-Kuwabara Y, Neves JI, Fregnani JH, et al. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization (FISH) and immunohistochemistry [ J ]. BMC Cancer, 2009,9 ( 6 ) : 1207-1471.
  • 5Dreilich M,Wanders A,Brattstrom D,et al. HER-2 overexpression (3 + ) in patients with squamous cell esophageal carcinoma correlates with poo- rer survival[ J ]. Dis Esophagus,2006,19 (4) :224-231.
  • 6PA B, Zhai R, Ma C, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis [ J 1. Clin Cancer Res, 2009,15 (14) :4680-4685.
  • 7KD C, Neugut A. Epidemiology of upper gastrointestinal malignan- cies [Jl. Semln Oncol, 2004,31 (4) : 450-464.
  • 8Menard S, Casalini P, Campiglio M, et al. HER2 overexpression in various tumor types, focusing on its relationship to the develop- ment of invasive breast cancer[ J]. Ann Oncol, 2001,12 ( Suppl 1) :15-19.
  • 9Wu DP, Xu J, Yu GM, et al. Expression status of fatty acid syn- thase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma[ J]. Hepatogastroen- terology, 2013,60( 121 ) :99-106.
  • 10Kato H, Arao T, Matsumoto K, et al. Gene amplification of EG- FR, HER2, FGFR2 and MET in esophageal squamous cell carci- noma[J~. Int J Oncol, 2013,42(4) :1151-1158.

引证文献3

二级引证文献8

癌变．畸变．突变
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部